Research programme: RNAi-based hepatitis C virus therapeutics - Tacere Therapeutics

Drug Profile

Research programme: RNAi-based hepatitis C virus therapeutics - Tacere Therapeutics

Alternative Names: OBP-701; RNAi HCV therapeutics - Tacere Therapeutics/Oncolys BioPharma; RNAi HCV therapeutics - Tacere Therapeutics/Pfizer; TT-033; TT-033i

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Benitec Ltd
  • Developer Tacere Therapeutics
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (IV, Injection)
  • 30 Oct 2012 Tacere Therapeutics has been acquired by Benitec Biopharma
  • 11 Oct 2012 Pfizer returns rights to the HCV programme to Tacere
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top